Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:26:13.538Z.
Calculation as of: 2026-10-06T14:26:13.538Z.
Quote observation: 2026-10-06T14:25:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$411.99M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$412.27M
EV/EBITDA Ratio
N/A
TTM Avg
30.26x
3Y Avg
22.88x
5Y Avg
18.64x
Market Cap
$406.54M
EV/EBITDA Ratio
N/A
TTM Avg
5.73x
3Y Avg
28.73x
5Y Avg
28.73x
Market Cap
$432.69M
EV/EBITDA Ratio
0.43x
TTM Avg
1.11x
3Y Avg
1.11x
5Y Avg
1.11x
Market Cap
$437.27M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $411.99M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $412.27M | N/A | 30.26x | 22.88x | 18.64x |
| Carlsmed, Inc. (CARL)vs › | $408.32M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.54M | N/A | 5.73x | 28.73x | 28.73x |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $402.01M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $425.86M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $432.69M | 0.43x | 1.11x | 1.11x | 1.11x |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.27M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $384.04M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
